Disease Detail


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown AZD8055 + Selumetinib rhabdomyosarcoma not applicable detail...
Unknown unknown BMS-754807 rhabdomyosarcoma not applicable detail...
Unknown unknown Dasatinib rhabdomyosarcoma not applicable detail...
Unknown unknown YM155 + Cisplatin rhabdomyosarcoma not applicable detail...
Unknown unknown JQ1 rhabdomyosarcoma not applicable detail...
Unknown unknown TAS4464 rhabdomyosarcoma not applicable detail...
Unknown unknown Prexasertib rhabdomyosarcoma not applicable detail...
NRAS Q61H Alpelisib + Binimetinib rhabdomyosarcoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting
NCT01446809 Phase I Doxorubicin + Ifosfamide Pazopanib + Doxorubicin + Ifosfamide Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Unknown status
NCT01518413 Phase I Sorafenib + Irinotecan Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed
NCT01661400 Phase I Cyclophosphamide Thalidomide Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors Recruiting
NCT01871766 Phase II Bevacizumab + Cyclophosphamide + Sorafenib Vincristine + Dactinomycin Vincristine + Dactinomycin + Cyclophosphamide Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery Recruiting
NCT02013336 Phase I Cyclophosphamide + MM-398 Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Recruiting
NCT02303028 Phase Ib/II Topotecan + Pazopanib Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours Recruiting
NCT02304458 Phase Ib/II Nivolumab + Ipilimumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Recruiting
NCT02372006 Phase I Afatinib Phase I Trial of Afatinib in Pediatric Tumours Recruiting
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting
NCT02567435 Phase III Vincristine + Dactinomycin + Cyclophosphamide Temsirolimus Irinotecan Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Recruiting
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Active, not recruiting
NCT03139331 Phase I Pazopanib + Irinotecan + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Recruiting
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Recruiting
NCT03245151 Phase Ib/II Everolimus + Lenvatinib Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Recruiting
NCT03441360 Phase II Eribulin Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Recruiting
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting